Page last updated: 2024-10-31

midodrine and Pulmonary Arterial Hypertension

midodrine has been researched along with Pulmonary Arterial Hypertension in 1 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Pulmonary Arterial Hypertension: A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.

Research Excerpts

ExcerptRelevanceReference
" Midodrine is an α1 vasoconstrictor commonly used for the treatment of pulmonary arterial hypertension (PAH) and intradialytic hypotension."7.91Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis. ( Alobaidi, A; Bielnicka, P; Drambarean, B, 2019)
" Midodrine is an α1 vasoconstrictor commonly used for the treatment of pulmonary arterial hypertension (PAH) and intradialytic hypotension."3.91Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis. ( Alobaidi, A; Bielnicka, P; Drambarean, B, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Drambarean, B1
Bielnicka, P1
Alobaidi, A1

Other Studies

1 other study available for midodrine and Pulmonary Arterial Hypertension

ArticleYear
Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Jan-01, Volume: 76, Issue:1

    Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Epoprostenol; Humans; Hypotension; Kidney

2019